Mental health care company raises $146.6 million on Nasdaq
London, 15 October 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised on the successful initial public offering (IPO) of COMPASS Pathways (“COMPASS”) on Nasdaq. The offering raised $146.6 million. COMPASS began trading on the Nasdaq Global Select Market on September 18, 2020 under the ticker symbol “CMPS”.
COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. It is pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support from specially trained therapists. Its initial focus is on treatment-resistant depression, an area of significant unmet medical need.
The Consilium team was led by Amber Fennell and supported by Chris Gardner, David Daley, Alix Floyd, Olivia Manser, Lizzie Seeley and Maya Bennison. Consilium continues to advise the company on its financial communications as a publicly listed company. Cowen, Evercore ISI and Berenberg acted as Joint Global Coordinators and Joint Bookrunners in the offering.
Proceeds from the IPO will be used to fund clinical trials, therapist training and other activities to support the development of COMPASS’ investigational COMP360 psilocybin therapy; to fund research and clinical development activities to support the progression of the COMP360 psilocybin therapy for other neuropsychiatric indications; to fund general business development activities; and to fund general and administrative expenses, working capital and other general corporate purposes.
“We are delighted to have supported COMPASS through this major milestone. The team at COMPASS have an impressive vision of a world of mental wellbeing which we are proud to help them communicate internationally. We look forward to supporting COMPASS as a listed company as it continues to transform mental health care.”
Amber Fennell
Partner and Co-Founder of Consilium Strategic Communications
Consilium also advised on the communications surrounding the Nasdaq listing of Silence Therapeutics, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, in September 2020. Silence Therapeutics is led by recently appointed President and CEO, Mark Rothera, based in US, and has commenced a search for a US based CFO as it strengthens its team and increases its visibility into the US.